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2Abstract – The emerging significance of recognition of cellular glycans by lectins for diverse 
aspects of pathophysiology is a strong incentive for considering development of bioactive and 
non-hydrolyzable glycoside derivatives, for example by introducing S/Se atoms and the 
disulfide group instead of oxygen into the glycosidic linkage. We report the synthesis of 12 
bivalent thio-, disulfido- and selenoglycosides attached to benzene/naphthalene cores. They 
present galactose, for blocking a plant toxin, or lactose, the canonical ligand of 
adhesion/growth-regulatory galectins. Modeling reveals unrestrained flexibility and inter-
headgroup distances too small to bridge two sites in the same lectin. Inhibitory activity was 
first detected by solid-phase assays using a surface-presented glycoprotein, with relative 
activity enhancements per sugar unit relative to free cognate sugar up to nearly 10fold. 
Inhibitory activity was also seen on lectin binding to surfaces of human carcinoma cells. In 
order to proceed to characterize this capacity in the tissue context monitoring of lectin binding 
in the presence of inhibitors was extended to sections of three types of murine organs as 
models. This procedure proved to be well-suited to determine relative activity levels of the 
glycocompounds to block binding of the toxin and different human galectins to natural 
glycoconjugates at different sites in sections. The results on most effective inhibition by two 
naphthalene-based disulfides and a selenide raise the perspective for broad applicability of the 
histochemical assay in testing glycoclusters that target biomedically relevant lectins.
Key words: Agglutinin; Glycosyldisulfides; Histochemistry; Lectin; Selenoglycosides; Sugar 
code; Thioglycosides
31. Introduction
A prominent hallmark of cell surfaces is the presentation of a wide array of glycans by 
cellular glycoconjugates. They are produced by intimately controlled and regulated 
glycosylation, often likened to a cell’s fingerprint that undergoes profound developmental and 
disease-associated alterations.1-6 Our view on the glycans’ (patho)physiological significance 
has matured from an initial interpretation as purely phenomenological markers to the current 
delineation of their nature as meaningful biochemical signals that harbor information encoded 
in sequence and shape, the basis of the concept of the sugar code.7-10 One route of translating 
this information into bioeffects is via functional pairing with sugar receptors (lectins), what 
explains the increasing attention to study protein-glycan recognition.11-13 
The available body of evidence underscores that the reactivity of glycans for lectins in situ 
critically depends on the presentation of the cognate epitope in a topologically suited manner, 
for example by branched N- or O-glycans or by microdomains in membranes. This interplay 
of complementary features on several levels sets limits for the expectation that binding 
partners in artificial laboratory assays will necessarily have the same characteristics as the 
operative counterreceptors on/in cells. In fact, the emerging insights into the remarkable 
selectivity of lectins for few distinct targets from the broad panel of cellular glycoconjugates 
give a strong incentive to work with synthetic cluster glycosides to measure the impact of 
topological properties. 14-16 Preferably, these compounds should have a glycosidic linkage that 
is resistant to hydrolysis by glycosidases, hereby enabling to consider a perspective for 
application as stable pharmaceutical inhibitor against toxins or harmful activities of tissue 
lectins. However, such a substitution, for example from oxygen in inter-residual bonds to 
thio- or selenoglycosidic linkages, entails alterations in bond angles (C-C-O: 115°; C-C-S/Se: 
95°) and length (C-O: 1.4 Å; C-S: 1.8 Å; C-Se: 1.9 Å). These changes raise the question on 
the capacity of the resulting products as competitive inhibitor of lectin binding to 
counterreceptors. This parameter is routinely tested by engaging glycoconjugates as assay 
platform, for example a glycoprotein. To meet the challenge of including topological features, 
established cell lines, commonly used for functional assays, offer an attractive system of 
increased relevance, and, indeed, work on the role of adhesins in pathogen-host recognition 
has recently emphasized “the critical importance of utilizing physiologically relevant cells”.17 
In order to monitor reduction of lectin binding to cells and the extracellular matrix in a single 
experimental setting in the tissue context, we here proceed to work with tissue sections.
4Thio- and dithioglycosides have gained special interest due to the thiol-disulfide conversion in 
dynamic combinatorial libraries of thioglycosides, broadened to the level of glycopeptides 
and -proteins.18-21 The facile preparation of symmetric glycosyldisulfides, in parallel, 
contributed to start exploring their bioactivity profiles.22-25 Remarkably, glycosyldisulfides, 
especially dithiodigalactoside, have already been identified as inhibitors for biomedically 
relevant plant agglutinins and, albeit less potently, human lectins,26, 27 and, more recently, 
seleno- and diselenodigalactosides have been found to share this property.28 In this report, 
first the synthesis of a panel of 12 bivalent benzene- or naphthalene-based thio-, disulfido- 
and selenoglycoside derivatives (Chart 1) is described. Running molecular-modeling 
protocols answers the question on the accessible conformational space, solid-phase lectin 
assays on potential for bioactivity by reduction of extent of binding to a glycoprotein by a 
plant toxin, i.e. Viscum album agglutinin,29 or by human adhesion/growth-regulatory 
galectins.30 Finally, the cell biological and histochemical experiments, using free sugar as 
control in parallel, determine this capacity, when the lectins are bound by cognate 
glycoconjugates on surfaces of tumor cells in culture as well as of cells and matrix in sections 
of fixed organ specimens.
2. Results and discussion
2.1. Chemistry
The panel of bivalent compounds is divided into the group of -galactoside-presenting 
derivatives 1-8 for testing with the plant toxin and the lactose-containing compounds 9-12 
(Chart 1). Naphthalene-based disulfides 1 and 2 and the thioglycoside 3 as well as the 
benzene- (4, 5) and naphthalene-based selenides (6-8) constitute the first group. Disulfides of 
aromatic cores (9-11) and a naphthalene-based thioglycoside derivative (12) establish the 
second group for testing binding to human galectins.
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Chart 1 Structures of thio-, disulfido- and selenoglycoside derivatives 1-12
The synthetic routes are summarized in Chart 2. As illustrated, the selenoglycosides 4-8 were 
prepared via reactions of bis(bromomethyl)benzenes or -naphthalenes (A) with 2,3,4,6-tetra-
O-acetyl-β-D-galactopyranosyl isoselenuronium bromide28 according to a published 
procedure31 followed by deacetylation. Similar reactions with 1-thio-2,3,4,6-tetra-O-acetyl-β-
D-galactopyranose32, 33and 1-thio-2,3,6-tri-O-acetyl-4-(2,3,4,6-tetra-O-acetyl-β-D-
galactopyranosyl)-β-D-glucopyranose34 resulted in the formation of compounds 3 and 12 after 
deacetylation. Aromatic bis(methanethiosulfonates) (B) provided the fully acetylated 
compounds 1, 2, 9, 10 and 11, which were deprotected by treatment with equivalent LiOH in 
6methanol. It is worth noting that the core’s extension from benzene to naphthalene can readily 
facilitate fluorescence measurements, and previous analysis of a respective lactose derivative 
with such an appendix has excluded a primarily non-specific (hydrophobic) binding to 
galectins.35 In order to gain insights into the accessible conformational space of the sugar 
headgroups attached to these aromatic cores, we performed molecular modeling.
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Chart 2 Syntheses of thio- and seleno derivatives 1-12 
92.2. Molecular modeling
Conformational parameters were computationally calculated exemplarily for the benzene-
based selenides 4 and 5 and the naphthalene-based disulfides 9 and 11 to infer any impact of 
positional effects (meta or para) on headgroup presentation. The models (built in Discovery 
Studio Visualizer 4.5 (Biovia)) for each compound were subjected to molecular dynamics 
(MD) calculations using General Amber Force Field (GAFF) in the AMBER14 simulation 
protocol at 298 K for 100 ns, with addition of an octahedral shell of explicit water molecules 
around the glycoside derivatives implemented in each case. A set of 10,000 structures was 
retained, all of which were analyzed.
In order to comparatively characterize the individual arrangements of the two pairs, three 
parameters were selected for documentation: i) the inter-headgroup separation of sugar units 
as defined by the distance between anomeric carbon centers, ii) the orientation of the lactose 
units by a pseudo torsion angle defined between the C4 atoms of galactose and the C1 atoms 
of glucose moieties, respectively, and iii) the orientation of galactose units by a pseudo 
torsion angle defined between the bond vectors of O4-C4 in galactose residues. The distance 
between the two sugar units in each pair was within the range of 4 Å to 11 Å (Fig. 1a, c, e, g). 
Obviously, the substitution pattern can slightly shift the distance profile, the meta-
constellation yielding smaller distances than a para-substitution. This information can be set 
into relation to the distances between carbohydrate-binding sites in lectins. Since the two 
contact regions characterized by the central Trp residues are at least 15 Å apart,36 a bridging 
of contact sites by a bivalent compound is hardly possible. Such a scenario has been reported 
for wheat germ agglutinin (WGA), where pairs of the total of eight adjacent binding sites 
were loaded by four fitting bivalent compounds.37 Interestingly, the same aim, that is high 
avidity to the lectin, had also been attained by cross-linking several WGA molecules.38 Such a 
mechanism could be affected in efficiency by restrictions in flexibility.
The scatter plots of pseudo torsion angles, shown in Fig. 1b, d for galactose-presenting 
compounds 4 and 5 and in Fig. 1f, h for lactose-presenting compounds 9 and 11, revealed 
accessibility to nearly the entire conformational space, with some preferences indicated by 
clustering. The results are in line with modeling of selenoglycosides using a force field 
version adapted for selenoglycosides that revealed similarities to the flexibility of 
thioglycosides.39 The headgroups are thus presented by both types of aromatic core in a 
10
flexible and dynamic manner, making lectin binding likely. This parameter is first assessed 
systematically by a solid-phase assay.
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Figure 1. Geometric parameters to define distances between and relative orientations of sugar units obtained by molecular dynamics simulations for 4 (a & b), 5 (c & d), 9 (e & f) and 11 (g & h). The plots depict changes of the separation between sugar units as defined by C1-C1’ distance (in Ǻ) of galactose units in 4 & 5 (a & c) and that of glucose residues of the lactose units in 9 & 11 (e & g) as a function of the pseudo torsion angles (in deg) as defined by GalC4-GalC1-GalC1’-GalC4’ for 4 & 5 and by GalC4-GlcC1-GlcC1’-GalC4’ for 9 & 11, respectively, denoted as the “core dihedral”; as well as variations of the pseudo torsion angles defined by the GalC4-GalO4-GalC4’-GalO4’ denoted as the “galactose dihedral” as a function of the core dihedrals for 4 & 5 (b & d) and for 9 & 11 (f & h).
2.3. Inhibition assays
A glycoprotein with up to nine binding sites for the tested lectins, i.e. asialofetuin (ASF), is 
adsorbed to the surface of microtiter plate wells. As consequence, a matrix is established for 
binding of labeled lectins by N-acetyllactosamine termini of the glycoprotein’s branched N-
glycans. The association of lectin to the glycoprotein is nearly completely inhibitable by 
cognate sugar, ascertaining its nature by glycan recognition, as demonstrated before in 
precipitation assays that yielded the expected 1:9 stoichiometry of ASF/VAA complexes at 
lectin saturation.40 Bound lectin is quantitated spectrophotometrically. Free galactose served 
as reference to determine the relative increase in inhibitory capacity by bivalent presentation. 
To avoid any turbidity of solutions compounds were in those cases first dissolved in DMSO, 
this clear solution then slowly added to buffer. However, aggregate formation cannot be 
excluded. Controls were then also run with the same final concentration of the aprotic solvent. 
Compounds 1 to 8 invariably proved to enhance the inhibitory capacity of free galactose by a 
factor from 2.5 up to nearly 10fold. The disulfide 2 and the selenide 6 reached highest levels 
in this respect, encouraging to test inhibition of lectin binding to cultured cells. When VAA 
formed contact to glycans on cell surfaces, the same tendency was observed, as shown in Fig. 
2a,b for compound 2 relative to galactose presented by two other scaffolds. This result 
confirms and extends previous experience with different structural modes for attaining 
bivalency.41-45 It qualifies these two compounds for the ensuing histochemical assay. 
Activity was similarly examined in the solid-phase and cell assays for endogenous lectins 
with compounds 9 - 12. Among the human galectins, proto-type (homodimeric) galectin-1, 
chimera-type galectin-3 and tandem-repeat-type galectin-8, representing the three modes of 
structural galectin design, are the most prominently studied members of this family.46-48 
Disease progression in osteoarthritis is a clinical example of harmful effects of these three 
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lectins.49-51 Disulfide 9 proved most active as inhibitor of glycoprotein binding in all three 
cases, whereas for example the thioglycoside 12 conveyed comparatively less increase of 
inhibitory capacity to lactose by conjugation to the scaffold. When testing the effect of 
presence of the cognate sugar on cell binding, the same tendency was seen. Figure 2c 
illustrates the superior inhibitory potency of compound 9 vs free lactose on galectin-3, Fig. 
2d,e on homodimeric wild-type galectin-1 and a covalently linked variant of this lectin and 
Fig. 2f on galectin-8. These observations explain why compound 9, together with a control 
(here compound 12), was taken to the histochemical evaluation of inhibition. In this assay, the 
labeled lectin will bind to reactive sites in the tissue section (control), and an inhibitor will 
decrease signal intensity in the specimen according to its capacity for competition with the 
underlying molecular interaction of the lectin with the different sites of positivity in the organ, 
all examined at the same time in the same section.
Figure 2. Flow cytofluorimetric analysis of extent of inhibition of lectin binding to cell surface glycans (tested on the human colon adenocarcinoma line SW480 (a-c) and the pancreatic carcinoma line Capan-1 reconstituted for expression of the human tumor suppressor p16INK4a (d-f)) by cognate sugar, free or as part of bivalent glycocompounds. Numbers in each panel give percentage of positive cells/mean fluorescence intensity, the grey curve represents the 0%-level (background control) in the absence of labeled lectin (set of numbers given on top of list in the right part of each illustration). VAA-dependent staining when increasing lectin concentration from 0.1 µg/mL to 0.2 µg/mL, 
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0.5 µg/mL, 1 µg/mL and 2 µg/mL (a) and with lectin (2 µg/mL fluorescent lectin) in the presence of 0.5 mM galactose presented by compound 2, of 2 mM by compound 8 and of 0.5 mM by compound 3 as well as in the absence of cognate sugar (100%-level) (curves from left to right, numbers in list from top to bottom) (b). Galectin-3-dependent staining (10 µg/mL biotinylated lectin) in the presence of 0.1 mM lactose presented by compound 9 and as free sugar as well as in the absence of sugar (c). Galectin-1-dependent staining (20 µg/mL fluorescent lectin) in the presence of 10 mM free lactose and of 1 mM lactose presented by compounds 9 and 11, respectively, as well as in the absence of sugar (d). Staining by the engineered galectin-1 variant with covalent connection of the two lectin domains (2 µg/mL fluorescent lectin) in the presence of 2 mM lactose presented by compound 9, 10 mM free lactose and 2 mM lactose presented by compound 11 as well as in the absence of sugar (e). Galectin-8-dependent staining (2 µg/mL fluorescent lectin) in the presence of 2 mM lactose presented by compound 9 and 10 mM free lactose as well as in the absence of sugar (f).
In the first stage of running this assay, staining was proven to be dependent on the presence of 
the labeled lectin and to be inhibitable by blocking lectin binding with cognate sugar. 
Galactose/lactose can completely block positivity so that lectin-independent mechanisms for 
signal generation could be excluded. The optimal concentration of labeled lectin, at which the 
signal-to-background ratio was best, was determined by systematically processing serial 
sections using stepwise increases from a broad concentration range of each lectin, i.e. 0.2-4 
µg/mL for VAA, 0.5-6 µg/mL for galectin-3, 0.125-2 µg/mL for galectin-1 and 0.25-2 µg/mL 
for galectin-8. These experiments establish the 100%-value and ensure inhibitability of 
binding by cognate sugar.
To illustrate the principle of this assay, results from systematic titrations with inhibitor in the 
case of labeled VAA and sections of fixed adult murine kidney are presented in Fig. 3. 
Stepwise increases of the concentration of free cognate sugar (galactose) led to corresponding 
decreases of positivity, from 100% to no binding, and a value of about 5 mM free galactose as 
inhibitory concentration to reduce signal intensity to 50% (IC50-value) (Fig. 3a-d). In 
comparison to the total experimental read-out in the two assays given above, microscopical 
evaluation of each section enables monitoring of various tissue constituents, that is the 
different cell types and extracellular matrix. Figure 3d provides the 0%-value for internal 
calibration.
15
Figure 3. Stepwise reduction of VAA-dependent staining in sections of fixed adult murine kidney by presence of increasing concentrations of cognate sugar (galactose). The lectin (at 1 µg/mL) bound strongly to epithelial lining and brush border of proximal tubules (P), whereas glomeruli (G) and distal tubules (D) remained mostly unstained. In titrations, the 100%-level of signal intensity was still obtained in the presence of 2 mM free galactose (a) and 0.1 mM of scaffold-presented galactose (by compound 2: e; by compound 6: i). Increases of sugar concentration (5 mM (b), 10 mM (c) and 50 mM (d) of free galactose; 0.5 mM (f, j), 1 mM (g, k) and 5 mM (h, l) galactose in disulfide 2 (e-h) and selenide 6 (i-l)) led to increasing degrees of inhibition of lectin binding. The corresponding category of signal intensity after semiquantitative grading is given in the bottom left part of each microphotograph, following intensity assessment according to the following system: -, no staining; (+), very weak but significant staining; +, weak staining; ++, medium-level staining; +++, strong staining; ++++, very strong staining. Scale bars: 20 µm.
Tested as inhibitor on toxin binding, compounds 2 and 6 were rather similarly active with 
IC50-values between 0.5 mM and 1 mM galactose (Fig. 3e-l), relative to the 5 mM value for 
free galactose. Broadening the experimental basis to two further organs, sections of murine 
epididymis (Fig. 4a-d), thoroughly studied with VAA previously52, and jejunum (Fig. 4e-h) 
were subjected to respective processing. As illustrated in Fig. 4 by presenting IC50-
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constellations, relative potency grading was similar. It is important to note that the 
microphotographs should be closely examined in all regions: signals in the striated border of 
epithelial cells in jejunum were significantly more susceptible to intensity decrease by 
compound presence than to presence of free galactose (Fig. 4e-h). The detection of such a 
regional disparity is a clear advantage of this assay. As the plant lectin does, tissue 
(endogenous) lectins also yield staining patterns, which depend on the nature of the lectin (for 
histological details, please see legend to figures).
Figure 4. Stepwise reduction of VAA-dependent staining in sections of the corpus region of fixed murine epididymis (a-d) and of jejunum (e-h) by presence of increasing concentrations of cognate sugar (galactose). The lectin (at 1 µg/mL) bound strongly to the epithelial lining of ductus epididymidis, here especially in the supranuclear area of principal cells (arrow), also to stereocilia on the luminal surface of principal cells (arrowhead) and luminal spermatozoa (S), shown in a. In jejunum, shown in e, lamina propria mucosae of villi intestinales (L) and glandulae intestinales (arrow) were main sites of strong signal intensity. No reduction of signal intensity was seen in the presence of up to 1 mM free galactose (a, e). For the two organs, presence of 5 mM/10 mM free galactose (b/f), of 0.5 mM/1 mM galactose presented by compound 2 (c/g) or 0.25 mM/1 mM galactose presented by compound 6 (d/h) inhibited lectin binding by about 50%. Staining of the striated border and cytoplasm of the epithelial lining (arrowheads) appears less affected by lactose (f) than by the lactoside derivatives (g, h). Complete inhibition was obtained at 50 mM free galactose (insets to a, e) and at 10 mM of scaffold-presented galactose (insets to c, g and to d, h). Scale bars: 20 µm.
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Figure 5. Stepwise reduction of galectin-3-dependent staining in sections of fixed murine jejunum by presence of increasing concentrations of cognate sugar (lactose). The lectin (at 4 µg/mL) bound strongly to epithelial cells in glandulae intestinales (asterisk) and also to the apical part of epithelial cells in villi intestinales (arrow). Goblet cells, in contrast, were negative (arrowhead). Staining intensity remained at the 100%-level in the presence of up to 5 µM lactose presented by compound 9 (a) and decreased when increasing the sugar concentration to 10 µM (b), 25 µM (c) and 50 µm (d). Testing the IC50 of lactose for this compound (at 25 µM of lactose) presented by compound 12 (e) and for free lactose (g) revealed less (e) or no (g) effect. The concentration for reaching 50%-level was 50 µM for the thioglycoside 12 (f) and 1 mM for free lactose (h). Scale bars: 20 µm.
In the case of galectin-3, the IC50-value of compound 9 for reducing signal intensity in 
sections of fixed murine jejunum was about 25 µM (Fig. 5a-d). Respective values were 50 
µM for lactose presented by compound 12 (Fig. 5e,f) and 1 mM for free lactose (Fig. 5g,h). 
An about 6-fold difference was determined in inhibitory potency of lactose presented by 
compound 9 and free lactose for galectin-1 (not shown), an about 100fold (50fold) difference 
between lactose presented by compound 9 (compound 12) and free lactose for galectin-8 (Fig. 
6a-d). In both cases, inhibitory potency appeared higher on lectin binding to tissue sections, 
between the synthetic compounds and lactose, than to the surface of the human tumor cells 
(Fig. 2d-f).
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Figure 6. Illustration of galectin-8-dependent staining in sections of fixed murine jejunum in the absence of cognate sugar (100%-level: a; inset to a: negative control without labeled lectin) and its reduction to 50%-level by cognate sugar as free lactose (b) or presented by compounds 9 and 12, respectively (c, d). Cytoplasm and striated border (arrowhead) of villi intestinales were stained by the lectin (0.33 µg/mL), even stronger signals were seen for epithelial cells of glandulae intestinales (arrow). Reduction to 50%-level was obtained in systematic titrations with 2.5 mM free lactose (b) as well as with 25 µM sugar presented by compound 9 (c) and 50 µM lactose presented by compound 12 (d), example for complete inhibition by 1 mM lactose presented by compound 12 given as inset to (d). Scale bars: 20 µm.
These three assays thus report on the effect of the synthetic compounds on lectin binding to 
different ligands, i.e. on N-glycans of a glycoprotein, cell surface-presented glycans of cells 
adapted to growth in culture and glycans in sections of fixed tissues. As advantage of the 
histochemical assay, the monitoring of tissue sections even provides evidence for regional 
differences of signal reduction by free and compound-presented cognate sugar, seen in 
jejunum and galectin-3-dependent staining in favor of the synthetic products 9 and 12. This 
observation underscores the potential of analyzing in parallel reduction of extent of positivity 
at diverse sites of an organ, represented in a section. For multifunctional effectors such as 
galectins, with counterreceptors in the glycocalyx such as laminin or fibronectin53-55, in the 
membrane such as integrins56 and in the cytoplasm or nucleus such as bcl-257, 58, respective 
information can be gleaned from a section, provided that tissue fixation did not harm 
reactivity. Moreover, considering a network of lectins, differential staining and reactivity 
patterns can be elucidated using the described protocol, as presented here for three human 
galectins.
3. Conclusions
This report extends the activity spectrum of thio-, disulfido- and selenogalactosides on a 
biohazard, i.e. a ricin-like toxin, to naphthalene-based disulfides and selenides presenting the 
cognate sugar galactose. The compounds had very little or no activity on human galectins, as 
already observed previously for mono-, bi- and trivalent disulfides attached to a benzene core 
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in meta-position.28 Among the four thioglycosides and disulfides with lactose as ligand part, 
the naphthalene-based compound 9 proved most effective for galectins, with relative 
differences in potency depending on the structural design of the lectin. These results underline 
that a thiol-disulfide conversion, as exploited in works with dynamic combinatorial libraries18-
20, 26, is an option for programming surface display and ligand density of 
glycodendrimersomes. These vesicle-like structures of adjustable architecture are versatile 
tools for measuring activity of galectins and other biomedically relevant lectins as 
intercellular glue.59-62
As part of soluble glycoclusters, involvement of S, Se atoms in the glycosidic bond confers 
distinct stereotopic and flexibility features to the sugar headgroup presentation. Its activity as 
lectin inhibitor is readily determined in a solid-phase assay (or related procedures; for 
compilation of methods, please see 63). Considering a perspective for biomedical applications, 
thorough inspection of an impact on lectin binding to physiological counterreceptors and of 
cross-reactivity among related sugar receptors then are the arising challenges to be adequately 
addressed. The histochemical protocol applied herein can take respective studies another step 
forward to the envisioned aim.
4. Experimental
4.1. Chemistry
4.1.1. General chemistry
1,4-, 1,5-, 2,6-Bis(bromomethyl)naphthalenes and 1,3-, 1,4-bis(bromomethyl)benzenes were 
commercial products, 2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl isoselenuronium 
bromide26, 1-thio-2,3,4,6-tetra-O-acetyl-β-D-galactopyranose32, 33 and 1-thio-2,3,6-tri-O-
acetyl-4-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-β-D-glucopyranose34 were prepared 
according to literature procedures. NMR spectra were recorded on a Bruker Avance II 500 
(500/125 MHz for 1H/13C) spectrometer. Chemical shifts are referenced to internal TMS (1H), 
or to the residual solvent signals (13C). Mass spectra were measured using a Bruker 
micrOTOFQ mass spectrometer. TLC was performed on DC-Alurolle Kieselgel F254 
(Merck), and the compounds on the plates were visualized under UV light and by heating. For 
column chromatography, Kieselgel 60 (Merck, particle size 0.063-0.200) was used. 
4.1.2. General procedure for the preparation of thioglycosides (3,12)
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1,4-Bis(bromomethyl)naphthalene was dissolved in DMF at r.t. stirring under nitrogen 
atmosphere, then the peracetylated glycosylthiol was added, followed by triethylamine. 
Stirring was continued at r.t. until TLC indicated complete conversion of the starting 
materials (30 min) to products, then the reaction mixture was poured into water. A solid 
deposited which was filtered, rinsed with 3x10 mL water, and dried, yielding crude 
peracetylated products. The crude products were dissolved in methanol, stoichiometric 
amounts of LiOH.H2O added for deacetylation at 0 °C. The reaction mixture was allowed to 
warm to r.t. and when the starting material had completely reacted (TLC), the pH was 
adjusted to neutral by cation exchange resin, the suspension filtered, and the filtrate 
evaporated to dryness. The residue was stirred in acetone for 30 minutes, filtered, washed 
with acetone and dried to yield the 1,4-bis(bromomethyl)naphthalene-based thioglycosides.
4.1.3. 1,4-Bis{1-[(β-D-galactopyranosyl)thio]methyl}naphthalene (3)
From 1,4-bis(bromomethyl)naphthalene (140 mg, 0.44 mmol), 2,3,4,6-tetra-O-acetyl-1-thio-
β-D-galactopyranose (324.9 mg, 0.89 mmol) and triethylamine (0.1 mL, 1.36 mmol) 340 mg 
(87 %) of crude peracetylated 3 were obtained. Deacetylation as described above produced 
56.4 mg (61 %) of 3. [α]D22 –243 (c 0.12 DMSO); 1H NMR (CD3OD-DMSO-d6, 500 MHz): δ 
8.23 (m, 2H, (H-5, H-8)Napht); 7.57 (m, 2H, (H-6, H-7)Napht); 7.39 (s, 2H, (H-2, H-3)Napht); 4.46 
(d, 2H, CH2a, Ja,b 13 Hz); 4.38 (d, 2H, CH2b); 4.25 (d, 2H, H-1,1’Gal, J1,2 9.7 Hz); 3.89 (d, 2H, 
H-4,4’Gal, J3,4 2.7 Hz); 3.83 (dd, 2H, H-6a,6a’Gal, J5,6a 7.0 Hz, J6a,6b 11.5 Hz); 3.75 (dd, 2H, H-
6b,6b’Gal, J5,6b 5.1 Hz); 3.60 (dd, 2H, H-2,2’Gal, J2,3 9.4 Hz); 3.52 (m, 2H, H-5,5’); 3.38 (dd, 
2H, H-3,3’Gal, J3,4 2.8 Hz, J2,3 9.2 Hz); 13C NMR (DMSO, 125 MHz): δ 134.16 (C-1, C-4)Napht; 
132.13 (C-1a, C-4a)Napht; 127.18 (C-2, C-3)Napht; 126.21 (C-6, C-7)Napht; 125.53 (C-5, C-
8)Napht; 84.57 (C-1,1’)Gal; 79.95 (C-5,5’)Gal; 75.18 (C-3,3’)Gal; 70.42 (C-2,2’)Gal; 69.03 (C-
4,4’)Gal; 61.33 (C-6,6’)Gal; 30.34 (CH2-S).
HRMS m/z Calcd for C24H32O10S2 [M+Na]+: 567.133. Found: 567.134.
4.1.4. 1,4-Bis{1-[(β-D-galactosyl-(1→4)-β-D-glucosyl)thio]methyl}naphthalene (12)
From 1,4-bis(bromomethyl)naphthalene (48.3 mg, 0.15 mmol), 1-thio-2,3,6-tri-O-acetyl-4-
(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-β-D-glucopyranose (201 mg, 0.31 mmol) and 
triethylamine (0.1 mL, 1.36 mmol) 168.3 mg (75 %) of crude 12 were obtained in 
peracetylated form. Deacetylation yielded 56.7 mg (63 %) of 12. [α]D22  – 92 (c 0.15 DMSO);
21
1H NMR (CD3OD, 500 MHz): δ  8.29 (m, 2H, (H-5, H-8)Napht); 7.57 (m, 2H, (H-6, H-7)Napht); 
7.46 (s, 2H, (H-2, H-3)Napht); 4.49 (d, 2H, CH2a,  Ja,b 13.1 Hz); 4.38 (m, 4H, CH2b, H-1,1’Gal  
J1,2 7.7 Hz); 4.27 (d, 2H, H-1,1’Glc, J1,2 9.8 Hz); 3.95 (dd, 2H, H-6,6’aGlc, J6a,6b 12.2 Hz, J5,6a 
2.6 Hz); 3.86 (dd, 2H, H-6,6’bGlc, J5,6b 4.6 Hz); 3.83 (d, 2H, H-4,4’Gal, J3,4 3.2 Hz); 3.78 (dd, 
2H, H-6,6’aGal, J6a,6b 11.5 Hz, J5,6a 3.9 Hz); 3.71 (dd, 2H, H-6,6’bGal, J5,6b 4.6 Hz); 3.59 (m, 
6H, H-5,5’Gal, H-4,4’Glc, H-2,2’Glc); 3.50 (dd, 2H, H-3,3’Gal,  J2,3 9.8 Hz, J3,4 3.2 Hz); 3.47 (m, 
2H, H-5,5’Glc); 3.44 (t, 2H, H-3,3’Glc,  J2,3 = J3,4 8.9 Hz); 3.34 (2H, H-2,2’Gal); 13C NMR 
(DMSO-d6, 125 MHz): δ 133.95 (C-1, C-4)Napht; 132.12 (C-1a, C-4a)Napht; 127.26 (C-2, C-
3)Napht; 126.27 (C-6, C-7)Napht; 125.56 (C-5, C-8)Napht; 104.34 (C-1,1’)Gal; 83.69 (C-1,1’)Glc; 
81.35 (C-5,5’)Glc; 79.67 (C-4,4’)Glc; 76.93 (C-2,2’)Gal; 75.98 (C-5,5’)Gal; 73.71 (C-3,3’)Gal; 
73.31 (C-3,3’)Glc; 71.00 (C-2,2’)Glc; 68.61 (C-4,4’)Gal; 61.25 (C-6,6’)Gal; 60.86 (C-6,6’)Glc; 
30.32 (CH2-S).
HRMS m/z Calcd for C36H52O20S2 [M+Na]+: 891.239. Found:  891.236.
4.1.5. General procedure for the preparation of glycosyl disulfides (1,2,9,10,11) 
Bis(methanesulfonylthiomethyl)arenes (B) were dissolved in 3 mL DMF at r.t. stirring under 
nitrogen atmosphere, peracetylated glycosylthiols were added, followed by triethylamine. 
Stirring was continued at r.t. until TLC indicated disappearance of the starting materials (30 
min), then processed as described in 4.1.2.
4.1.6. 1,5-Bis{1-[(β-D-galactopyranosyl)dithio]methyl}naphthalene (1)
From 1,5-bis(methanesulfonylthiomethyl)naphthalene (95.1 mg, 0.25 mmol), 
1-thio-2,3,4,6-tetra-O-acetyl-β-D-galactopyranose (184.0 mg, 0.50 mmol) and triethylamine 
(0.1 mL, 1.36 mmol) 177 mg (74 %) of crude peracetylated 1 were obtained. Deacetylation 
yielded 68.9 mg (71 %) of 1. [α]D22 – 40 (c 0.19 DMSO); 1H NMR (CD3OD, 500 MHz): δ 
8.25 (d, 2H, (H-4, H-8)Napht); 7.53 (d, 2H, (H-2, H-6)Napht); 7.49 (t, 2H, (H-3, H-7)Napht); 4.67 
(d, 2H, CH2a) 4.57 (d, 2H, CH2b  Ja,b 10 Hz); 4.34 (d, 2H, H-1,1’Gal, J1,2 9.8 Hz); 3.94 (m, 4H, 
H-4,4’Gal, H-6a,6a’Gal); 3.81 (m, 4H, H-6b,6b’Gal, H-2,2’Gal); 3.59 (m, 2H, H-5,5’Gal ); 3.53 (m, 
2H, H-3,3’Gal); 13C NMR (DMSO-d6, 125 MHz):  δ 133.68 (C-1, C-5)Napht; 132.00 (C-1a, C-
4a)Napht; 128.93 (C-2, C-6)Napht; 126.22 (C-3, C-7)Napht; 125.35 (C-8, C-4)Napht; 91.97 (C-
1,1’)Gal; 80.27 (C-5,5’)Gal; 75.09 (C-3,3’)Gal; 68.96 (C-2,2’)Gal; 68.76 (C-4,4’)Gal; 61.39 (C-
6,6’)Gal; 42.24 (CH2-S).
HRMS m/z Calcd for C24H32O10S4 [M+Na]+: 631.078. Found:  631.073.
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4.1.7. 1,4-Bis{1-[(β-D-galactopyranosyl)dithio]methyl}naphthalene (2)
From 1,4-bis(methansulfonylthiomethyl)naphthalene (206.8 mg, 0.55 mmol), 
1-thio-2,3,4,6-tetra-O-acetyl-β-D-galactopyranose (400.0 mg, 1.10 mmol) and triethylamine 
(0.4 mL, 5.45 mmol) 406 mg (78 %) of crude peracetylated 2 were generated. Deacetylation 
yielded 55.9 mg (58 %) of 2. [α]D22 – 64 (c 0.16 DMSO); 1H NMR (CD3OD-DMSO-d6, 500 
MHz): δ  8.34 (m, 2H, (H-5, H-8)Napht); 7.62 (m, 2H, (H-6, H-7)Napht); 7.50 (s, 2H, (H-2, H-
3)Napht); 4.65 (d, 2H, CH2a) 4.55 (d, 2H, CH2b  Ja,b 10 Hz); 4.35 (d, 2H, H-1,1’Gal, J1,2 9.8 Hz); 
3.97 (dd, 2H, H-4,4’Gal, J3,4 3.2 Hz J4,5 ~1 Hz); 3.82 (dd, 2H, H-6a,6a’Gal, J5,6a 7.2 Hz, J6a,6b 
11.9 Hz); 3.86 (dd, 2H, H-6b,6b’Gal, J5,6b 5.1 Hz); 3.81 (t, 2H, H-2,2’Gal, J2,3 =J1,2 9.4  Hz); 
3.64 (m, 2H, H-5,5’Gal ); 3.57 (dd, 2H, H-3,3’Gal); 13C NMR (DMSO-d6, 125 MHz):  δ 133.30 
(C-1, C-4)Napht; 131.89 (C-1a, C-4a)Napht; 128.37 (C-2, C-3)Napht; 126.74 (C-6, C-7)Napht; 
125.67 (C-5, C-8)Napht; 91.99 (C-1,1’)Gal; 80.26 (C-5,5’)Gal; 75.09 (C-3,3’)Gal; 68.96 (C-
2,2’)Gal; 68.75 (C-4,4’)Gal; 61.39 (C-6,6’)Gal; 42.02 (CH2-S).
HRMS m/z Calcd for C24H32O10S4 [M+Na]+: 631.078. Found: 631.075. 
4.1.8. 1,4-Bis{1-[(β-D-galactosyl-(1→4)-β-D-glucosyl)dithio]methyl}naphthalene (9)
586.1 mg (70 %) of crude peracetylated 9 were produced from 1,4-
bis(methanesulfonylthiomethyl)naphthalene (206.8 mg, 0.55 mmol), 
1-thio-2,3,6-tri-O-acetyl-4-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-β-D-glucopyranose 
(717.0 mg, 1.10 mmol) and triethylamine (0.21 mL, 2.86 mmol). Deacetylation yielded 67.7 
mg (75 %) of 9. [α]D22 –173 (c 0.19 DMSO);
1H NMR (CD3OD, 500 MHz): δ 8.25 (m, 2H, (H-5, H-8)Napht); 7.59 (m, 2H, (H-6, H-7)Napht); 
7.46 (s, 2H, (H-2, H-3)Napht); 4.61 (d, 2H, CH2a) 4.56 (d, 2H, CH2b  Ja,b 12.2 Hz); 4.43 (d, 2H, 
H-1,1’Gal, J1,2 7.7 Hz); 4.34 (d, 2H, H-1,1’Glc, J1,2 9.4 Hz); 3.94 (dd, 2H, H-6a,6a’Glc, J6a,6b 12.2 
Hz, J5,6a 2.1 Hz); 3.89 (dd, 2H, H-6b,6b’Glc, J5,6b 4.0 Hz); 3.83 (d, 2H, H-4,4’Gal, J3,4 2.5 Hz); 
3.80 (d, 2H, H-6a,6a’Gal, J6a,6b 11.3 Hz); 3.72 (dd, 2H, H-6b,6b’Gal, J5,6b 4.5 Hz); 3.67 (m, 4H, 
H-4,4’Glc, H-2,2’Glc); 3.63 (m, 2H, H-5,5’Gal); 3.57 (m, 4H, H-3,3’Glc, H-2,2’Gal); 3.50 (dd, 2H, 
H-3,3’Gal,  J2,3 9.7 Hz, J3,4 3.1 Hz); 3.42 (m, 2H, H-5,5’Glc); 13C NMR (DMSO-d6, 125 MHz): 
δ 133.30 (C-1, C-4)Napht; 131.82 (C-1a, C-4a)Napht; 128.46 (C-2, C-3)Napht; 126.57 (C-6, C-
7)Napht; 125.54 (C-5, C-8)Napht; 104.18 (C-1,1’)Gal; 90.12 (C-1,1’)Glc; 80.34 (C-5,5’)Glc; 79.84 
(C-4,4’)Glc; 76.61 (C-2,2’)Gal; 76.07 (C-5,5’)Gal; 73.73 (C-3,3’)Gal; 71.42 (C-3,3’)Glc; 71.02 (C-
2,2’)Glc; 68.66 (C-4,4’)Gal; 61.00 (C-6,6’)Gal; 60.92 (C-6,6’)Glc; 41.72 (CH2-S).
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HRMS m/z Calcd for C36H52O20S4 [M+Na]+: 955.183. Found:  955.179.
4.1.9. 1,4-Bis{1-[(β-D-galactosyl-(1→4)-β-D-glucosyl)dithio]methyl}benzene (10)
From 1,4-bis(methanesulfonylthiomethyl)benzene (179.3 mg, 0.55 mmol), 1-thio-2,3,6-tri-O-
acetyl-4-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-β-D-glucopyranose (717.0 mg, 1.1 
mmol) and triethylamine (0.21 mL, 2.86 mmol) 491.1 mg (61 %) of crude peracetylated 10 
were obtained. Deacetylation yielded 59.3 mg (66 %) of 10. [α]D22 – 5 (c 0.13 DMSO);  1H 
NMR (CD3OD, 500 MHz): δ 7.31 (s, 4H)Xyl; 4.44 (d, 2H, CH2a,  Ja,b 9.1 Hz); 4.38 (d, 2H, H-
1,1’Gal, J1,2 7.7 Hz); 4.35 (d, 2H, CH2b); 4.30 (d, 2H, H-1,1’Glc, J1,2 9.3 Hz); 3.92 (d, 2H, H-
6a,6a’Glc, J6a,6b 12.2 Hz); 3.84 (dd, 2H, H-6b,6b’Glc, J5,6b 4.2 Hz); 3.80 (s, 2H, H-4,4’Gal); 3.77 
(d, 2H, H-6a,6a’Gal, J6a,6b 11.4 Hz); 3.70 (dd, 2H, H-6b,6b’Gal, J5,6b 4.7 Hz); 3.58 (m, 6H, H-
4,4’Glc, H-2,2’Glc, H-5,5’Gal); 3.47 (m, 6H, H-3,3’Gal, H-3,3’Glc, H-2,2’Gal); 3.43 (m, 2H, H-
5,5’Gal); 13C NMR (DMSO-d6, 125 MHz): δ 136.85 (C-1, C-4)Xyl; 129.91 (C-2, C-3, C-5, C-
6)Xyl; 104.19 (C-1,1’)Gal; 90.11 (C-1,1’)Glc; 80.55 (C-5,5’)Glc; 79.67 (C-4,4’)Glc; 76.61 (C-
2,2’)Gal; 76.01 (C-5,5’)Gal; 73.73 (C-3,3’)Gal; 71.55 (C-3,3’)Glc; 71.01 (C-2,2’)Glc; 68.62 (C-
4,4’)Gal; 61.01 (C-6,6’)Gal; 60.89 (C-6,6’)Glc; 43.31 (CH2-S).
HRMS m/z Calcd for C32H50O20S4 [M+Na]+: 905.168. Found: 905.167  .
4.1.10. 1,5-Bis{1-[(β-D-galactosyl-(1→4)-β-D-glucosyl)dithio]methyl}naphthalene (11)
The reaction mixture with 1,5-bis(methanesulfonylthiomethyl)naphthalene (110.1 mg, 0.29 
mmol), 
1-thio-2,3,6-tri-O-acetyl-4-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-β-D-glucopyranose   
(381.7 mg, 0.58 mmol) and triethylamine (0.1 mL, 1.36 mmol) let us reach a yield of 295.1 
mg (66 %) of crude peracetylated 11. 55.9 mg (58 %) of 11 was obtained after deacetylation. 
[α]D22 – 13 (c 0.13 DMSO); 1H NMR (CD3OD, 500 MHz): δ 8.21 (d, 2H, (H-4, H-8)Napht); 
7.53 (d, 2H, (H-2, H-6)Napht); 7.49 (t, 2H, (H-3, H-7)Napht); 4.63 (d, 2H, CH2a) 4.57 (d, 2H, 
CH2b  Ja,b 12.1 Hz); 4.43 (d, 2H, H-1,1’Gal, J1,2 7.6 Hz); 4.34 (d, 2H, H-1,1’Glc, J1,2 9.4 Hz); 
3.95 (dd, 2H, H-6a,6a’Glc, J6a,6b 12.2 Hz, J5,6a 2.0 Hz); 3.89 (dd, 2H, H-6b,6b’Glc, J5,6b 4.1 Hz); 
3.83 (d, 2H, H-4,4’Gal, J3,4 2.5 Hz); 3.81 (d, 2H, H-6a,6a’Gal, J6a,6b 11.3 Hz); 3.72 (dd, 2H, H-
6b,6b’Gal, J5,6b 4.5 Hz); 3.68 (m, 4H, H-4,4’Glc, H-2,2’Glc); 3.63 (m, 2H, H-5,5’Gal); 3.57 (m, 
4H, H-3,3’Glc, H-2,2’Gal); 3.50 (dd, 2H, H-3,3’Gal,  J2,3 9.75 Hz); 3.43 (m, 2H, H-5,5’Glc); 13C 
NMR (DMSO-d6, 125 MHz):  δ 133.95 (C-1, C-5)Napht; 131.93 (C-1a, C-4a)Napht; 129.00 (C-2, 
C-6)Napht; 126.03 (C-3, C-7)Napht; 125.09 (C-8, C-4)Napht; 104.19 (C-1,1’)Gal; 90.13 (C-1,1’)Glc; 
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80.37 (C-5,5’)Glc; 79.84 (C-4,4’)Glc; 76.62 (C-2,2’)Gal; 76.06 (C-5,5’)Gal; 73.72 (C-3,3’)Gal; 
71.43 (C-3,3’)Glc; 71.03 (C-2,2’)Glc; 68.65 (C-4,4’)Gal; 61.01 (C-6,6’)Gal; 60.92 (C-6,6’)Glc; 
42.00 (CH2-S).
HRMS m/z Calcd for C35H50O20S4 [M+Na]+: 955.183. Found: 955.181.
4.1.11. General procedure for the preparation of selenoglycosides (4,5,6,7,8)
Bis(bromomethyl)arenes (A) were dissolved in DMF at r.t. stirring under nitrogen 
atmosphere, 2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl isoselenuronium bromide was 
added, followed by triethylamine. Stirring was continued at r.t. until TLC indicated 
consumption of the starting materials (30 min,) then the reaction mixture was poured into 
water (30 mL). The formed solid was filtered, rinsed with 3x10 mL water and dried, yielding 
crude peracetylated products. Deacetylation was effected as described under 4.1.2.
4.1.12. 1,3-Bis{1-[(β-D-galactopyranosyl)seleno]methyl}benzene (4)
From 1,3-bis(bromomethyl)benzene (120 mg, 0.45 mmol), 2,3,4,6-tetra-O-acetyl-β-D-
galactopyranosyl isoselenuronium bromide (486 mg, 0.91 mmol) and triethylamine (0.21 mL, 
2.86 mmol) led to 421.8 mg (96 %) of crude peracetylated 4. 75.0 mg (79 %) of 4 was 
obtained after deacetylation. [α]D22 –137 (c 0.17 DMSO); 1H NMR (CD3OD-DMSO-d6, 500 
MHz): δ 7.39 (m, 1H)Xyl; 7.21 (m, 3H)Xyl; 4.41 (d, 2H, H-1,1’Gal, J1,2 9.9 Hz); 4.12 (d, 2H, 
CH2a) 3.87 (d, 2H, CH2b  Ja,b 11.6 Hz);  3.89 (dd, 2H, H-4,4’Gal, J3,4 3.4 Hz J4,5 0.7 Hz); 3.84 
(dd, 2H, H-6a,6a’Gal, J5,6a 7.1 Hz, J6a,6b 11.2 Hz); 3.74 (dd, 2H, H-6b,6b’Gal, J5,6b 5.0 Hz); 3.69 
(t, 2H, H-2,2’Gal, J2,3 =J1,2 9.2  Hz); 3.58 (m, 2H, H-5,5’Gal ); 3.38 (dd, 2H, H-3,3’Gal ); 13C 
NMR (DMSO-d6, 125 MHz):  δ 140.26 (C-1, C-3)Xyl; 129.93 (C-2)Xyl; 128.65 (C-5)Xyl; 
127.34 (C-4, C-6)Xyl; 81.11 (C-1,1’)Gal; 79.94 (C-5,5’)Gal; 75.18 (C-3,3’)Gal; 71.51 (C-2,2’)Gal; 
69.15 (C-4,4’)Gal; 61.29 (C-6,6’)Gal; 24.94 (CH2-Se).
HRMS m/z Calcd for C20H30O10Se2 [M+Na]+: 613.007. Found: 613.007.
4.1.13. 1,4-Bis{1-[(β-D-galactopyranosyl)seleno]methyl}benzene (5)
Starting with 1,4-bis(bromomethyl)benzene (120 mg, 0.45 mmol), 2,3,4,6-tetra-O-acetyl-β-D-
galactopyranosyl isoselenuronium bromide (486 mg, 0.91 mmol) and triethylamine (0.21 mL, 
2.86 mmol) 372 mg (88 %) of crude peracetylated 5 were synthesized. Deacetylation yielded 
60.6 mg (64 %) of 5. [α]D22 – 197 (c 0.15 DMSO); 1H NMR (CD3OD-DMSO-d6, 500 MHz): δ 
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7.30 (s, 4H)Xyl; 4.46 (d, 2H, H-1,1’Gal, J1,2 9.8 Hz); 4.09 (d, 2H, CH2a) 3.91 (d, 2H, CH2b  Ja,b 
11.6 Hz);  3.88 (dd, 2H, H-4,4’Gal, J3,4 3.5 Hz J4,5 ~1 Hz); 3.79 (dd, 2H, H-6a,6a’Gal, J5,6a 7.2 
Hz, J6a,6b 11.6 Hz); 3.71 (dd, 2H, H-6b,6b’Gal, J5,6b 5.1 Hz); 3.67 (t, 2H, H-2,2’Gal, J2,3 =J1,2 9.2  
Hz); 3.47 (m, 2H, H-5,5’Gal ); 3.77 (dd, 2H, H-3,3’Gal); 13C NMR (DMSO-d6, 125 MHz):  δ 
138.36 (C-1, C-4)Xyl; 129.27 (C-2, C-3, C-5, C-6)Xyl; 81.14 (C-1,1’)Gal; 80.09 (C-5,5’)Gal; 
75.16 (C-3,3’)Gal; 71.54 (C-2,2’)Gal; 69.08 (C-4,4’)Gal; 61.21 (C-6,6’)Gal; 24.83 (CH2-Se).
HRMS m/z Calcd for C20H30O10Se2 [M+Na]+: 613.007. Found: 613.006.
4.1.14. 2,6-Bis{1-[(β-D-galactopyranosyl)seleno]methyl}naphthalene (6)
From 2,6-bis(bromomethyl)naphthalene (120 mg, 0.38 mmol), 2,3,4,6-tetra-O-acetyl-β-D-
galactopyranosyl isoselenuronium bromide (410 mg, 0.76 mmol) and triethylamine (0.21 mL, 
2.86 mmol) 200 mg (54 %) of peracetylated 6 were obtained. Deacetylation yielded 67.6 mg 
(69 %) of 6. [α]D22 – 201 (c 0.14 DMSO); 1H NMR (CD3OD-DMSO-d6, 500 MHz): δ  7.65 (s, 
2H, (H-1, H-5)Napht); 7.64 (d, 2H, (H-4, H-8)Napht); 7.39 (dd, 2H, (H-3, H-7)Napht); 4.29 (d, 2H, 
H-1,1Gal, J1,2 9.8 Hz); 4.16 (d, 2H, CH2a) 3.92 (d, 2H, CH2b  Ja,b 11.8 Hz);  3.75 (dd, 2H, H-
4,4‘Gal, J3,4 3.3 Hz J4,5 ~1 Hz); 3.71 (dd, 2H, H-6a,6a‘Gal, J5,6a 7.2 Hz, J6a,6b 11.9 Hz); 3.61 (dd, 
2H, H-6b,6b‘Gal, J5,6b 5.1 Hz); 3.57 (t, 2H, H-2,2‘Gal, J2,3 =J1,2 9.8  Hz); 3.33 (m, 2H, H-
5,5‘Gal); 3.20 (dd, 2H, H-3,3‘Gal); 13C NMR (DMSO-d6, 125 MHz):  δ 137.41 (C-2, C-6)Napht; 
132.10 (C-1a, C-4a)Napht; 128.35 (C-4, C-8)Napht; 127.98 (C-3, C-7)Napht; 127.09 (C-1, C-
5)Napht; 81.38 (C-1,1‘)Gal; 79.80 (C-5,5‘)Gal; 75.17 (C-3,3‘)Gal; 71.49 (C-2,2‘)Gal; 69.22 (C-
4,4‘)Gal; 61.47 (C-6,6‘)Gal; 25.28 (CH2-Se).
HRMS m/z Calcd for C24H32O10Se [M+Na]+: 663.022. Found:  663.024.
4.1.15. 1,4-Bis{1-[(β-D-galactopyranosyl)seleno]methyl}naphthalene (7)
From 1,4-bis(bromomethyl)naphthalene (240 mg, 0.76 mmol), 2,3,4,6-tetra-O-acetyl-β-D-
galactopyranosyl isoselenuronium bromide (820 mg, 1.53 mmol) and triethylamine (0.4 mL, 
5.45 mmol) 557 mg (75 %) of crude peracetylated 7 were produced. 82.1 mg (84 %) of 7 was 
obtained after deacetylation. [α]D22 –271 (c 0.12 DMSO); 1H NMR (CD3OD-DMSO-d6, 500 
MHz): δ  8.22 (m, 2H)Napht); 7.57 (m, 2HNapht); 7.37 (s, 2HNapht); 4.40 (d, 2H, H-1,1‘Gal, J1,2 9.8 
Hz); 4.41 (d, 2H, CH2a); 4.30 (d, 2H, CH2b  Ja,b 11.9 Hz);  3.77 (dd, 2H, H-4,4‘Gal, J3,4 3.2 Hz 
J4,5 ~1 Hz); 3.71 (dd, 2H, H-6a,6a‘Gal, J5,6a 7.2 Hz, J6a,6b 11.9 Hz); 3.62 (dd, 2H, H-6b,6b‘Gal, 
J5,6b 5.1 Hz); 3.56 (t, 2H, H-2,2‘Gal, J2,3 = 9.4  Hz); 3.40 (m, 2H, H-5,5‘Gal ); 3.24 (dd, 2H, H-
3,3‘Gal); 13C NMR (DMSO-d6, 125 MHz):  δ 135.19 (C-1, C-4)Napht; 131.94 (C-1a, C-4a)Napht; 
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126.82 (C-2, C-3)Napht; 126.07 (C-6, C-7)Napht; 125.52 (C-5, C-8)Napht; 81.29 (C-1,1‘)Gal; 80.62 
(C-5,5‘)Gal; 75.18 (C-3,3‘)Gal; 71.51 (C-2,2‘)Gal; 69.14 (C-4,4‘)Gal; 61.34 (C-6,6‘)Gal; 22.58 
(CH2-Se).
HRMS m/z Calcd for C24H32O10Se [M+Na]+: 663.022. Found: 663.020.
4.1.16. 1,5-Bis{1-[(β-D-galactopyranosyl)seleno]methyl}naphthalene (8)
From 1,5-bis(bromomethyl)naphthalene (240 mg, 0.76 mmol), 2,3,4,6-tetra-O-acetyl-β-D-
galactopyranosyl isoselenuronium bromide (820 mg, 1.53 mmol) and triethylamine (0.4 mL, 
5.45 mmol) a yield of 410 mg (55 %) of crude peracetylated 8 was reached. 88.6 mg (90 %) 
of 8 was obtained after deacetylation. [α]D22 – 321 (c 0.12 DMSO); 1H NMR (CD3OD-
DMSO-d6, 500 MHz): δ  8.19 (d, 2H, (H-4, H-8)Napht); 7.56 (d, 2H, (H-2, H-6)Napht); 7.50 (t, 
2H, (H-3, H-7)Napht); 4.58 (d, 2H, CH2a); 4.56 (d, 2H, H-1,1’Gal, J1,2 9.8 Hz); 4.46 (d, 2H, CH2b  
Ja,b 11.9 Hz); 3.92 (dd, 2H, H-4,4’Gal , J3,4 3.3 Hz J4,5 ~1 Hz); 3.86 (dd, 2H, H-6a,6a’Gal J5,6a 7.0 
Hz, J6a,6b 11.9 Hz); 3.77 (dd, 2H, H-6b,6b’Gal J5,6b 5.2 Hz); 3.70 (t, 2H, H-2,2’Gal J2,3 = J1,2); 
3.56 (m, 2H, H-5,5’Gal); 3.39 (dd, 2H, H-3,3’Gal); 13C NMR (DMSO-d6, 125 MHz):  δ 136.50 
(C-1, C-5)Napht; 131.99 (C-1a, C-4a)Napht; 127.18 (C-2, C-6)Napht; 125.65 (C-3, C-7)Napht; 
124.16 (C-8, C-4)Napht; 81.37 (C-1,1’)Gal; 80.36 (C-5,5’)Gal; 75.18 (C-3,3’)Gal; 71.52 (C-
2,2’)Gal; 69.20 (C-4,4’)Gal; 61.41 (C-6,6’)Gal; 22.68 (CH2-Se).
HRMS m/z Calcd for C24H32O10Se [M+Na]+: 663.022. Found: 663.022.
4.2. Biochemistry
The plant toxin was obtained from dried mistletoe leaves, human galectins from recombinant 
production, then the proteins were purified from extracts by affinity chromatography as 
crucial step and rigorously controlled for purity by two-dimensional gel electrophoresis and 
mass spectrometry prior to labeling, as described.26, 28, 64, 65 Matrix for binding of labeled 
lectin (VAA: 1,2 µg/mL; galectin-3: 3 µg/mL: galectin-8: 0.3 µg/mL) was established by 
adsorption of ASF (0.5 µg/50 µl) to the surface of microtiter plate wells and further 
processing with signal development by enzymatic reaction of sensor conjugate 
streptavidin/peroxidase (Sigma, Munich, Germany) was performed as described in detail 
previously.26, 28 In the cases of turbidity of solutions of the glycocompounds in buffer, stock 
solutions were prepared in DMSO, as then also done for the controls.
4.3. Cell biology 
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Cells of the two human carcinoma line were grown and processed in FACScan analysis using 
the sensor conjugate streptavidin/R-phycoerythrin (Sigma) as described previously.26, 28
4.4. Histochemistry
Tissue specimen from four six-week-old C57BL/6 mice were fixed in Bouin’s solution and 
processed to obtain sections (about 5 µm) as described.66-68 Blocking of non-specific binding 
sites for proteins, specificity controls, the optimized staining protocol using biotinylated 
lectins and commercial kit reagents for signal development, documentation and 
semiquantitative assessment were carried out as described.67, 68
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Legends
Chart 1 Structures of thio-, disulfido- and selenoglycoside derivatives 1-12
Chart 2 Syntheses of thio- and seleno derivatives 1-12 
Figure 1. Geometric parameters to define distances between and relative orientations of sugar units obtained by molecular dynamics simulations for 4 (a & b), 5 (c & d), 9 (e & f) and  11 (g & h). The plots depict changes of the separation between sugar units as defined by C1-C1’ distance (in Ǻ) of galactose units in 4 & 5 (a & c) and that of glucose residues of the lactose units in 9 & 11 (e & g) as a function of the pseudo torsion angles (in deg) as defined by GalC4-GalC1-GalC1’-GalC4’ for 4 & 5 and by GalC4-GlcC1-GlcC1’-GalC4’ for 9 & 11, respectively, denoted as the “core dihedral”; as well as variations of the pseudo torsion angles defined by the GalC4-GalO4-GalC4’-GalO4’ denoted as the “galactose dihedral” as a function of the core dihedrals for 4 & 5 (b & d) and for 9 & 11 (f & h).
Figure 2.  Flow cytofluorimetric analysis of extent of inhibition of lectin binding to cell surface glycans (tested on the human colon adenocarcinoma line SW480 (a-c) and the pancreatic carcinoma line Capan-1 reconstituted for expression of the human tumor suppressor p16INK4a (d-f)) by cognate sugar, free or as part of bivalent glycocompounds. Numbers in each panel give percentage of positive cells/mean fluorescence intensity, the grey curve represents the 0%-level (background control) in the absence of labeled lectin (set of numbers given on top of list in the right part of each illustration). VAA-dependent staining when increasing lectin concentration from 0.1 µg/mL to 0.2 µg/mL, 
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0.5 µg/mL, 1 µg/mL and 2 µg/mL (a) and with lectin (2 µg/mL fluorescent lectin) in the presence of 0.5 mM galactose presented by compound 2, of 2 mM by compound 8 and of 0.5 mM by compound 3 as well as in the absence of cognate sugar (100%-level) (curves from left to right, numbers in list from top to bottom) (b). Galectin-3-dependent staining (10 µg/mL biotinylated lectin) in the presence of 0.1 mM lactose presented by compound 9 and as free sugar as well as in the absence of sugar (c). Galectin-1-dependent staining (20 µg/mL fluorescent lectin) in the presence of 10 mM free lactose and of 1 mM lactose presented by compounds 9 and 11, respectively, as well as in the absence of sugar (d). Staining by the engineered galectin-1 variant with covalent connection of the two lectin domains (2 µg/mL fluorescent lectin) in the presence of 2 mM lactose presented by compound 9, 10 mM free lactose and 2 mM lactose presented by compound 11 as well as in the absence of sugar (e). Galectin-8-dependent staining (2 µg/mL fluorescent lectin) in the presence of 2 mM lactose presented by compound 9 and 10 mM free lactose as well as in the absence of sugar (f).
Figure 3. Stepwise reduction of VAA-dependent staining in sections of fixed adult murine kidney by presence of increasing concentrations of cognate sugar (galactose). The lectin (at 1 µg/mL) bound strongly to epithelial lining and brush border of proximal tubules (P), whereas glomeruli (G) and distal tubules (D) remained mostly unstained. In titrations, the 100%-level of signal intensity was still obtained in the presence of 2 mM free galactose (a) and 0.1 mM of scaffold-presented galactose (by compound 2: e; by compound 6: i). Increases of sugar concentration (5 mM (b), 10 mM (c) and 50 mM (d) of free galactose; 0.5 mM (f, j), 1 mM (g, k) and 5 mM (h, l) galactose in disulfide 2 (e-h) and selenide 6 (i-l)) led to increasing degrees of inhibition of lectin binding. The corresponding category of signal intensity after semiquantitative grading is given in the bottom left part of each microphotograph, following intensity assessment according to 
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the following system: -, no staining; (+), very weak but significant staining; +, weak staining; ++, medium-level staining; +++, strong staining; ++++, very strong staining. Scale bars: 20 µm.
Figure 4. Stepwise reduction of VAA-dependent staining in sections of the corpus region of fixed murine epididymis (a-d) and of jejunum (e-h) by presence of increasing concentrations of cognate sugar (galactose). The lectin (at 1 µg/mL) bound strongly to the epithelial lining of ductus epididymidis, here especially in the supranuclear area of principal cells (arrow), also to stereocilia on the luminal surface of principal cells (arrowhead) and luminal spermatozoa (S), shown in a. In jejunum, shown in e, lamina propria mucosae of villi intestinales (L) and glandulae intestinales (arrow) were main sites of strong signal intensity. No reduction of signal intensity was seen in the presence of up to 1 mM free galactose (a, e). For the two organs, presence of 5 mM/10 mM free galactose (b/f), of 0.5 mM/1 mM galactose presented by compound 2 (c/g) or 0.25 mM/1 mM galactose presented by compound 6 (d/h) inhibited lectin binding by about 50%. Staining of the striated border and cytoplasm of the epithelial lining (arrowheads) appears less affected by lactose (f) than by the lactoside derivatives (g, h). Complete inhibition was obtained at 50 mM free galactose (insets to a, e) and at 10 mM of scaffold-presented galactose (insets to c, g and to d, h). Scale bars: 20 µm.
Figure 5. Stepwise reduction of galectin-3-dependent staining in sections of fixed murine jejunum by presence of increasing concentrations of cognate sugar (lactose). The lectin (at 4 µg/mL) bound strongly to epithelial cells in glandulae intestinales (asterisk) and also to the apical part of epithelial cells in villi intestinales (arrow). Goblet cells, in contrast, were negative (arrowhead). Staining intensity remained at the 100%-level in the presence of up to 5 µM lactose presented by compound 9 (a) and decreased when 
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increasing the sugar concentration to 10 µM (b), 25 µM (c) and 50 µm (d). Testing the IC50 of lactose for this compound (at 25 µM of lactose) presented by compound 12 (e) and for free lactose (g) revealed less (e) or no (g) effect. The concentration for reaching 50%-level was 50 µM for the thioglycoside 12 (f) and 1 mM for free lactose (h). Scale bars: 20 µm.
Figure 6. Illustration of galectin-8-dependent staining in sections of fixed murine jejunum in the absence of cognate sugar (100%-level: a; inset to a: negative control without labeled lectin) and its reduction to 50%-level by cognate sugar as free lactose (b) or presented by compounds 9 and 12, respectively (c, d). Cytoplasm and striated border (arrowhead) of villi intestinales were stained by the lectin (0.33 µg/mL), even stronger signals were seen for epithelial cells of glandulae intestinales (arrow). Reduction to 50%-level was obtained in systematic titrations with 2.5 mM free lactose (b) as well as with 25 µM sugar presented by compound 9 (c) and 50 µM lactose presented by compound 12 (d), example for complete inhibition by 1 mM lactose presented by compound 12 given as inset to (d). Scale bars: 20 µm.
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